Post-earnings recap
Reported
Mon, Jul 29, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report reflects ongoing challenges for CRISPR Therapeutics, particularly in achieving profitability. The lack of revenue figures and guidance may have contributed to the stock's slight decline of 1.16%. Investors may be concerned about the company's ability to generate revenue in the near term, despite its focus on research and development.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.01 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management appears cautious about future performance, focusing on long-term goals rather than immediate financial results. They did not provide specific guidance for upcoming quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company emphasized ongoing research and development efforts.